Fortress Biotech Subsidiary Helocyte Announces Grant that Could Provide Over $20 Million from National Institute of Allergy and Infectious Diseases for Phase 2 Study of Triplex for Control of Cytomegalovirus in Patients Undergoing Liver Transplantation

Link Type
Funded-research
Media Type
Article
Publish or Event Date
Link URL
https://www.fortressbiotech.com/investors/news-events/press-releases/detail/468/fortress-biotech-subsidiary-helocyte-announces-grant-that
Research Institution
Fortress Biotech
Short Title
Fortress Biotech Subsidiary Helocyte Announces Grant that Could Provide Over $20 Million in Patients Undergoing Liver Transplantation
Content Coordinator
Claudia Wair
Content Manager
Catey Laube Macdonald